Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nextcure Inc.

0.3612
+0.02647.89%
Post-market: 0.36120.00000.00%19:09 EDT
Volume:236.55K
Turnover:79.90K
Market Cap:10.12M
PE:-0.18
High:0.3650
Open:0.3390
Low:0.3210
Close:0.3348
Loading ...

Company Profile

Company Name:
Nextcure Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
43
Office Location:
9000 Virginia Manor Road,Suite 200,Beltsville,Maryland,United States
Zip Code:
20705
Fax:
- -
Introduction:
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Directors

Name
Position
Michael Richman
President, Chief Executive Officer and Director
David Kabakoff
Chair of our Board of Director
Briggs W. Morrison
Director
Chau Q. Khuong
Director
Elaine V. Jones
Director
Judith J. Li
Director
Stella Xu
Director
Stephen W. Webster
Director
Timothy M. Shannon
Director

Shareholders

Name
Position
Michael Richman
President, Chief Executive Officer and Director
Linda Liu
Senior Vice President, Research
Steven P. Cobourn
Chief Financial Officer
Timothy Mayer
Senior Vice President, Corporate Development
James B. Bingham
Chief Development Officer
Kevin N. Heller
Chief Medical Officer
Sol Langermann
Chief Scientific Officer